Full video transcriptClick to expand
Auto-generated transcript of @silversglowup's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Oh
@silversglowup's tirzepatide injection video, fact-checked
Quick answer
Tirzepatide is a dual GLP-1/GIP receptor agonist approved as Mounjaro for type 2 diabetes and Zepbound for weight management. In the SURMOUNT-1 trial, it produced 20.9% weight loss at the highest dose over 72 weeks in adults with obesity.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @silversglowup's tirzepatide injection video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@silversglowup's tirzepatide injection video, fact-checked" from ᴠɪᴄᴛᴏʀʏ sɪʟᴠᴇʀ. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist approved as Mounjaro for type 2 diabetes and Zepbound for weight management.
The reason this review is not generic is the source wording and the canonical claim label "glp1 mounjaro jab day arm shot wellnessjourney wellnesslifesty." In this clip, the useful excerpt is: "Oh" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide is a dual GLP-1/GIP receptor agonist approved as Mounjaro for type 2 diabetes and Zepbound for weight management.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide is a dual GLP-1/GIP receptor agonist approved as Mounjaro for type 2 diabetes and Zepbound for weight management. In the SURMOUNT-1 trial, it produced 20.9% weight loss at the highest dose over 72 weeks in adults with obesity.
- Tirzepatide produced 20.9% weight loss in the SURMOUNT-1 trial over 72 weeks in adults with obesity
- Upper arm injection is FDA-approved and appropriate for tirzepatide administration
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide produced 20.9% weight loss in the SURMOUNT-1 trial over 72 weeks in adults with obesity
- Upper arm injection is FDA-approved and appropriate for tirzepatide administration
- The medication requires a prescription and is approved for BMI ≥30 or BMI ≥27 with complications
- Common side effects include nausea (20.7% of participants), vomiting, and diarrhea
- Monthly cost can exceed $1,000 without insurance coverage
- Participants regained about half their lost weight when stopping medication in SURMOUNT-4
- Framing prescription weight management drugs as wellness products minimizes their medical nature
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
This TikTok from @silversglowup shows someone injecting Mounjaro (tirzepatide) into their arm while using wellness and weight management hashtags. The video doesn't make explicit medical claims, but let's examine what's happening here.
What does this video actually show?
The creator is injecting Mounjaro into their upper arm and framing it as part of their "wellness journey." They're using the correct hashtag #glp1agonist, which suggests they understand what type of medication this is.
The injection technique appears standard. Most people inject tirzepatide in the abdomen, thigh, or upper arm, rotating sites to prevent lipodystrophy. The arm is a perfectly valid injection site.
What's interesting is the wellness framing. Mounjaro isn't a wellness supplement or lifestyle enhancement. It's a prescription medication approved by the FDA for type 2 diabetes, with Zepbound (same active ingredient) approved specifically for weight management.
Is the arm injection technique correct?
Yes, injecting tirzepatide in the upper arm is medically appropriate. The prescribing information specifically lists the upper arm as an approved injection site alongside the abdomen and thigh.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) that led to Zepbound's approval didn't specify injection sites, but clinical practice supports rotating between all three areas. Some people find the arm more convenient or less sensitive than abdominal injections.
However, proper injection technique matters. You should pinch the skin, inject at a 90-degree angle, and hold for 6 seconds after injection. The video is too brief to assess whether these steps were followed correctly.
What's misleading about the wellness framing?
Calling tirzepatide part of a "wellness journey" downplays what this medication actually is. This isn't a vitamin or supplement you pick up for general health.
Tirzepatide works by activating GLP-1 and GIP receptors, slowing gastric emptying and reducing appetite. In SURMOUNT-1, participants lost an average of 20.9% of body weight on the 15mg dose over 72 weeks. That's not wellness optimization, that's significant metabolic intervention.
The side effect profile includes nausea (experienced by 20.7% of participants), vomiting, diarrhea, and potential pancreatitis. Real medications have real risks that wellness language tends to minimize.
Does the science support using tirzepatide for weight loss?
Absolutely, but only in specific populations. The SURMOUNT trials showed impressive results, with participants losing 15-22.5% of body weight depending on the dose.
The FDA approved Zepbound (tirzepatide) for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. This isn't approved for people who want to lose 10 pounds for aesthetic reasons.
The SURMOUNT-1 trial enrolled people with an average BMI of 38. These were individuals with obesity, not people looking to optimize their wellness. The medication showed clear benefits in this population, reducing cardiovascular risk factors and improving quality of life measures.
However, we don't have long-term data beyond 72 weeks. The SURMOUNT-4 trial showed that people regained about half the weight they'd lost when they stopped the medication.
What should you know about tirzepatide?
First, this requires a prescription and medical supervision. You can't just decide to start this as part of your wellness routine.
The dosing schedule matters. Most people start at 2.5mg weekly, increasing by 2.5mg every 4 weeks up to a maximum of 15mg. The gradual increase helps minimize gastrointestinal side effects, which are common early on.
Cost is significant. Without insurance coverage, tirzepatide can cost over $1,000 monthly. Insurance coverage varies widely, and many plans don't cover it for weight management specifically.
@silversglowup gets credit for showing proper injection technique and using accurate hashtags. But framing prescription weight management medication as general wellness content misses the mark on what this drug actually represents.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
ᴠɪᴄᴛᴏʀʏ sɪʟᴠᴇʀ · TikTok creator
183.9K views on this video
Mounjaro jab day arm shot #wellnessjourney #wellnesslifestyle #glp1agonist #fyp #shotday
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide produced 20.9% weight loss in the surmount-1 trial over?
Tirzepatide produced 20.9% weight loss in the SURMOUNT-1 trial over 72 weeks in adults with obesity
What does the video say about upper arm injection?
Upper arm injection is FDA-approved and appropriate for tirzepatide administration
What does the video say about the medication requires a prescription?
The medication requires a prescription and is approved for BMI ≥30 or BMI ≥27 with complications
What does the video say about common side effects include nausea (20.7% of participants), vomiting,?
Common side effects include nausea (20.7% of participants), vomiting, and diarrhea
What does the video say about monthly cost can exceed $1,000 without insurance coverage?
Monthly cost can exceed $1,000 without insurance coverage
What does the video say about participants regained about half their lost weight?
Participants regained about half their lost weight when stopping medication in SURMOUNT-4
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ᴠɪᴄᴛᴏʀʏ sɪʟᴠᴇʀ, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.